Pharmacy Medical News about Osteoporosis, Postmenopausal ibandronate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study
Journal of Bone and Mineral Metabolism, 11/06/09

Li M et al. – The results observed in Chinese patients may support the observation that intravenous ibandronate significantly reduced bone resorption and increased BMD with good tolerance in Chinese postmenopausal osteoporotic women. Use of intravenous ibandronate possibly could potentially improve compliance as compared with other oral bisphosphonates because it may avoid the peptic side effects of oral bisphosphonate.

<< Previous
Serum homocysteine, folate and vitamin B12 in patients with...

Next >>
Satraplatin: leading the new generation of oral platinum agents

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Therapeutics and Clinical Risk Management, 10/16/09 Relevance Score: 69%

Combination of Two Medications Help Postmenopausal Women with Osteoporosis
MedLinePlus, 10/30/09 Relevance Score: 68%

Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09 Relevance Score: 67%

Bazedoxifene acetate: A novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis
Drugs of Today, 11/05/09 Relevance Score: 67%

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg
Current Medical Research and Opinion, 10/23/09 Relevance Score: 67%